Halozyme Therapeutics reported $541.94M in Current Assets for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
DBV Technologies DBVT:US 259.95M 169.52M
Acadia Pharmaceuticals ACAD:US $ 532.52M 9.7M
Agios Pharmaceuticals AGIO:US $ 870.01M 105.14M
Alnylam Pharmaceuticals ALNY:US $ 2471.64M 118.04M
Amarin AMRN:US $ 719.12M 53.5M
Amgen AMGN:US $ 19322M 802M
Baxter International BAX:US $ 7882M 291M
Cara Therapeutics CARA:US $ 176.17M 24.4M
Cytokinetics CYTK:US $ 602.25M 21.28M
Eli Lilly And LLY:US $ 17115.2M 150.5M
Esperion Therapeutics ESPR:US $ 252.48M 38.34M
Halozyme Therapeutics HALO:US $ 541.94M 446.75M
Immunogen IMGN:US $ 373.87M 82.84M
Intercept Pharmaceuticals ICPT:US $ 487.02M 9.66M
Intra Cellular Therapies ITCI:US $ 789.21M 59.14M
Intrexon XON:US $ 164.62M 9.68M
JAZZ PHA JAZZ:US $ 2590.83M 89.98M
Mannkind MNKD:US $ 193.48M 9.21M
Minerva Neurosciences NERV:US $ 50.04M 5.66M
Nektar Therapeutics NKTR:US $ 665.54M 67.92M
Peregrine Pharmaceuticals PPHM:US $ 180.02M 23.47M
Rigel Pharmaceuticals RIGL:US $ 120.52M 18.42M
United Therapeutics UTHR:US $ 2684.3M 97.7M
Vanda Pharmaceuticals VNDA:US $ 496.9M 4.63M